Indivior Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. (ticker: INDV) is a specialty biopharmaceutical company focused on the treatment of opioid use disorder (OUD). For more than 25 years, the company has been built around a narrow but highly relevant mission: to develop science-based therapies that expand access to treatment, reduce stigma, and support long-term recovery. INDV is now listed in the United States on the NASDAQ market, and its headquarters are in Richmond / North Chesterfield, Virginia, United States. From a historical standpoint, Indivior traces its roots to the separation of Reckitt Benckiser’s addiction-treatment pharmaceutical business in 2014. That origin shaped the company into a focused specialist rather than a broad-based pharma group. Its development strategy has consistently centered on addiction medicine, especially OUD, and in early 2026 the group completed its redomiciliation to the United States, with Indivior Pharmaceuticals, Inc. becoming the new parent company. The company’s core business revolves around medications used in OUD treatment, with a particular emphasis on long-acting formulations. Its flagship asset is SUBLOCADE®, a once-monthly extended-release buprenorphine injection positioned as a leading treatment for moderate to severe OUD. The commercial portfolio also includes SUBOXONE® Film, PERSERIS® (extended-release risperidone injection), and OPVEE® (nalmefene nasal spray), although recent strategy points to a sharper focus on the highest-value assets, particularly SUBLOCADE. In 2025, Indivior also received FDA approval for label changes to SUBLOCADE, which reinforced the product’s clinical and commercial profile. Competitive positioning is built on specialization. Indivior is not trying to compete as a diversified large-cap pharma company; instead, it occupies a niche leadership position in addiction treatment, with strong brand recognition among clinicians, payers, and public-health stakeholders. Its value proposition combines product innovation, medical education, access initiatives, and advocacy for viewing OUD as a chronic, treatable disease. Geographically, the company remains active internationally, but its operational and commercial profile has become increasingly U.S.-centric, reflecting the importance of the American market to its earnings base. Recent company commentary has also highlighted research and advocacy work around incarcerated populations, where access to medication for OUD remains a major unmet need. Recent milestones have been notable. In 2025, Indivior announced the end of its secondary listing in London while maintaining its primary listing on NASDAQ. Late in 2025, the company was added to the S&P SmallCap 600, a positive signal for capital markets visibility. More recently, 2025 and 2026 financial updates have continued to emphasize SUBLOCADE’s growth and the company’s strategic refocusing on its core addiction-medicine franchise.